The Effect of Zalunfiban on High Sensitivity Cardiac Troponin and the Association with Clinical Outcomes in Patients with STEMI
Listen to this summary
This study investigates the effects of zalunfiban, a glycoprotein IIb/IIIa receptor blocker, on high sensitivity cardiac troponin (hs-cTnT) levels and clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI). The authors found that higher hs-cTnT concentrations at presentation were linked to worse reperfusion metrics and increased short-term mortality and heart failure risk, while zalunfiban treatment was associated with reduced hs-cTnT levels and smaller myocardial infarction size. Overall, the findings suggest that zalunfiban may improve outcomes in STEMI patients by mitigating myocardial injury.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from American heart journal
View all →Jun 23, 2026 · American heart journal
DOAC Score Among Patients Receiving Vitamin K Antagonists
Jun 22, 2026 · American heart journal
Considerations for Using Atrial Fibrillation Burden as a Surrogate Endpoint A Report from the Cardiovascular Sciences Research Consortium
Jun 21, 2026 · American heart journal
Prognostic Impact of Combined Inflammatory Markers in Patients Undergoing Percutaneous Coronary Intervention
Jun 20, 2026 · American heart journal
Lessons Learned from the Feasibility Phase of the REvascularization CHoices Among Under-Represented Groups Evaluation (RECHARGE) Trial Program
Jun 20, 2026 · American heart journal
The Association of Single Ventricle Morphology with Long Term Quality of Life Among Survivors: A Report from CHD PULSE (Congenital Heart Disease Project to Understand Lifelong Survivor Experience)
Jun 19, 2026 · American heart journal
Registry of Atrial Fibrillation in Latin America: Primary Results of the LACROSS Study
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
